VM:CC - Voyageur Secures $687k of Additional Capital from Warrant Exercises

(TheNewswire)

• Voyageur streamlines capitalizationtable through exercise of 5,725,829 warrants, expiry of 8,844,935warrants

• Strong existing shareholder support,raising gross proceeds of $687,099

Calgary, Alberta, Canada – January 23, 2025 – TheNewswire - VoyageurPharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“ Voyageur ” or the“ Company ”), a company planning to vertically integrate the medicalimaging industry, is pleased to announce that it has receivedsignificant investor support, as effective January 20, 2025, theCompany received aggregate gross proceeds of $687,099 through theexercise of 5,725,829 share purchase warrants (“ Warrants ”),resulting in the issuance of  an aggregate of 5,725,829 common sharesof the Company (“ CommonShares ”). The Warrants were issued pursuant toa second closing of a private placement of units of the Company thatclosed on January 20, 2023, pursuant to which an aggregate of14,570,764 Warrants were issued. Following the exercises, 8,844,935Warrants expired unexercised. In addition, in December 2024, anadditional 2,571,369 Warrants expired unexercised, furtherstreamlining the capitalization table.

Brent Willis, Voyageur’s President, CEO and Director,expressed, “We sincerely appreciate the support our existinginvestors have placed in us. The warrant exercises will give Voyageuradded flexibility in achieving its goals to become a leader in theradiology drug market”.

Voyageur achieved significant milestones in 2024 andmanagement believes it is poised for further success in 2025. TheCompany strengthened partnerships, introduced innovative products, andexpanded leadership roles to drive growth. Voyageur completed a CAD$2.7 million sales contract on May 28,2024 , entered into a Letter of Intentwith a major multinational company on December 20,2024 , and is preparing to launch fiveHealth Canada licensed barium contrast products into market this year.With plans in 2025 for FDA applications for the barium sulfatecontrast media product line, strategic partnerships, and advancing theiodine contrast project, Voyageur’s management believes it is ontrack to become a leader in the radiology drug market with itsvertically integrated supply chain. Voyageur’s focus on pioneeringnew drug development programs and fostering collaborations underscoresits commitment to innovation and healthcare advancement.

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadian public company trading under thesymbol VM on the TSXV, is in development of barium and iodine ActivePharmaceutical Ingredients (API) and intends to offerhigh-performance, cost-effective imaging contrast agents. With astrategic focus on vertically integrating the barium and iodinecontrast markets, Voyageur aims to become a key player by producingits own barium, iodine, and new endohedral fullerene drugs (C60).Voyageur has developed five barium contrast products that have HealthCanada licenses.

Voyageur's business plan is set to generate cash flowby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada thereby ensuring the validation of itsproducts by regulatory agencies worldwide. As Voyageur solidifies itspresence in the market, it plans to transition into a high-margindomestic manufacturer of radiology drugs, further expanding itsrevenue streams.

At the core of its operations, Voyageur owns a 100% interest in the Frances Creek barium sulphate (barite) project.Currently, the world’s pharmaceutical barium sulphate is almostentirely synthetically produced which management believes results in aless effective imaging quality product. Voyageur’s Frances Creekresource boasts a rare and exceptional grade mineral suitable for thepharmaceutical marketplace that Voyageur believes will replace thecurrent synthetic products with higher quality lower cost imagingproducts.

Voyageur's ambitious vision is to become the firstvertically integrated company in the radiology contrast media drugmarket. By controlling all primary input costs, from the sourcing ofraw materials to final production, Voyageur intends to ensure qualityand cost efficiency. With its approach, it embodies the motto of" From the Earth to theBottle ," highlighting Voyageur's commitmentto responsible sourcing and manufacturing practices.

For Further Information:

Neither the TSX Venture Exchange nor its Regulation ServicesProvider (as that term is defined in the policies of the TSX VentureExchange) accepts responsibility for the adequacy or accuracy of thisnews release.

Cautionary Statement Regarding “Forward-Looking”Information

Thisnews release may contain certain forward-looking statements andforward-looking information (collectively, "forward-lookingstatements"), including without limitation, the Company’sbusiness plan and the Company’s plans in 2025. Forward-lookingstatements normally contain words like "will","intend", "anticipate", "could","should", "may", "might","expect", "estimate", "forecast","plan", "potential", "project","assume", "contemplate", "believe","shall", "scheduled", and similar terms.Forward-looking statements are not guarantees of future performance,actions, or developments and are based on expectations, assumptions,and other factors that management currently believes are relevant,reasonable, and appropriate in the circumstances. Although managementbelieves that the forward-looking statements herein are reasonable,actual results could be substantially different due to the risks anduncertainties associated with and inherent to Voyageur's business.Additional material risks and uncertainties applicable to theforward-looking statements herein include, without limitation, theimpact of general economic conditions, and unforeseen events anddevelopments. This list is not exhaustive of the factors that mayaffect the Company's forward-looking statements. Many of these factorsare beyond the control of Voyageur. All forward-looking statementsincluded in this news release are expressly qualified in theirentirety by these cautionary statements. The forward-lookingstatements contained in this news release are made as at the datehereof, and Voyageur undertakes no obligation to update publicly or torevise any of the included forward-looking statements, whether as aresult of new information, future events, or otherwise, except as maybe required by applicable securities laws. Risks and uncertaintiesabout the Company's business are more fully discussed under theheading "Risk Factors" in its most recent filings. They areotherwise disclosed in its filings with securities regulatoryauthorities available on SEDAR+ at www.sedarplus.ca.

Copyright (c) 2025 TheNewswire - All rights reserved.